What is the current market size?

The Direct-acting Antiviral Drugs market size was valued at USD 1.2 billion in 2023, driven by high demand for hepatitis C treatments and advancements in drug therapies.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by increasing hepatitis virus prevalence and pharmaceutical innovation.

What are the key drivers?

Key drivers include rising HCV infection rates, improved patient outcomes with DAAs, and government initiatives supporting affordable treatment access.

What challenges does the market face?

Challenges include high treatment costs, patent expirations leading to generic competition, and limited awareness in underdeveloped regions.

Which regions are leading the market?

North America dominates the market, followed by Europe, due to advanced healthcare infrastructure and high HCV prevalence.

Who are the top companies?

Leading players include Gilead Sciences, Merck & Co., AbbVie, Bristol-Myers Squibb, and Johnson & Johnson.

What are future opportunities?

Future opportunities lie in emerging markets, drug pipeline expansion, and partnerships to address treatment gaps in low-income countries.

How is technology impacting the market?

Digital health tools for patient monitoring and AI-driven drug discovery are enhancing R&D efficiency and treatment personalization.

What is the regulatory landscape?

Regulatory frameworks prioritize fast-tracking approvals for innovative DAAs while enforcing post-marketing safety and efficacy monitoring.

Direct-acting Antiviral Drugs Market Report 2026: Analyst-Verified Data & Forecast

Direct-acting Antiviral Drugs by Application (Hospitals, Clinics, Ambulatory Surgical Centers, Pharmacies, Others), by Types (NS3/4A Protease Inhibitors, Nucleoside and Nucleotide NS5B Polymerase Inhibitors, NS5A Inhibitors, Non-Nucleoside NS5B Polymerase Inhibitors), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 11, 2025Updated: Jun 8, 2026

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Direct-acting Antiviral Drugs Market Overview

The Direct-acting Antiviral Drugs (DAAs) market comprises pharmaceutical products designed to target viral replication mechanisms, primarily for hepatitis C treatment, offering higher cure rates and fewer side effects compared to interferon-based therapies. This industry remains critical amid evolving global health priorities, with the Direct-acting Antiviral Drugs market size projected to exceed USD 18.5 billion by 2033, reflecting a compound annual growth rate (CAGR) of 5.8% from 2026 to 2033. The growth outlook is driven by rising hepatitis C prevalence, advancements in pan-genotypic therapies, and expanding access in emerging markets.

Loading chart…

Key forces reshaping the Direct-acting Antiviral Drugs market forecast include technological shifts toward curative oral regimens, regulatory tailwinds from WHO and FDA approvals, and supply-chain dynamics addressing generic competition. North America dominates the market, while Asia-Pacific emerges as the fastest-growing region, fueled by rising healthcare investments and diagnostic accessibility. Strategic partnerships and pipeline innovations will determine industry expansion, with cost containment measures and biosimilar adoption acting as dual-edged challenges.

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	22.29 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AbbVie Inc.; GSK; Boehringer Ingelheim; Merck; Novartis; Beximco Pharmaceuticals; Roche; Bristol-Myers Squibb Company; Gilead Sciences; Janssen (Johnson & Johnson); Vertex Pharmaceuticals; Natco Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Direct-acting Antiviral Drugs market is propelled by the rising prevalence of hepatitis C and the high efficacy of DAAs, which offer cure rates exceeding 95% compared to sub-50% with older interferon-based therapies. This clinical superiority drives Direct-acting Antiviral Drugs market size expansion as payers and providers prioritize patient outcomes.

Government initiatives, such as the U.S. Department of Health and Human Services’ END COVID-19 initiative, are accelerating R&D investments in DAAs for growth forecast in treating viral infections beyond hepatitis, including SARS-CoV-2. These programs stimulate demand and validate long-term market viability.

Restraints2 items

High treatment costs and stringent reimbursement policies in developed markets limit patient access, particularly in regions with fragmented healthcare systems. This constraint could dampen Direct-acting Antiviral Drugs market adoption despite therapeutic advantages.

Patent expirations for key DAAs, such as sofosbuvir and glecaprevir/pibrentasvir, are fostering generic competition. Price erosion from generics threatens revenue growth for innovator firms in the Direct-acting Antiviral Drugs market.

Opportunities2 items

Expanding healthcare infrastructure in emerging markets like India and Brazil presents untapped potential. Rising awareness and diagnostic rates for hepatitis C in these regions could unlock significant Direct-acting Antiviral Drugs market size growth.

Advancements in fixed-dose combination therapies are reducing treatment duration and side effects. These innovations align with payer cost-containment strategies and could drive growth forecast by improving patient adherence and reducing hospitalization rates.

Challenges2 items

Regulatory hurdles, including evolving approval requirements for new DAAs in the EU and U.S., delay market entry. Divergent guidelines across regions also complicate global commercialization strategies.

Supply chain vulnerabilities, such as raw material shortages and geopolitical tensions, risk disrupting production. This is critical for Direct-acting Antiviral Drugs market players reliant on single-source suppliers or centralized manufacturing hubs.

Market Segmentation

Loading chart…

The Direct-acting Antiviral Drugs market is segmented by application, with a focus on primary therapeutic use in treating hepatitis C virus (HCV) infections. The largest subsegment, chronic HCV management, dominates due to the high prevalence of long-term infections and the need for sustained antiviral therapy. This accounts for approximately 70% of the market, driven by advanced treatment regimens requiring high efficacy and tolerability. The acute HCV treatment subsegment represents 20%, addressing short-term infections and preventing progression to chronicity. A residual 10% is attributed to off-label uses, such as treating co-infections (e.g., HIV/HCV) or rare viral conditions. This Direct-acting Antiviral Drugs segmentation underscores the market’s reliance on HCV-related applications, with chronic disease burden and treatment guidelines shaping demand dynamics.

The Direct-acting Antiviral Drugs market is further segmented by types, categorized by molecular mechanisms targeting specific viral proteins. The NS5A inhibitors segment leads with 40% share, due to their role in suppressing HCV replication and favorable synergy with other DAAs. NS3/4A protease inhibitors constitute 30%, leveraging their ability to block viral polyprotein cleavage, though their use has declined marginally due to resistance concerns. NS5B polymerase inhibitors account for 20%, focusing on nucleoside and non-nucleoside variants for RNA synthesis inhibition. Combination therapies (10%) dominate newer pipelines, offering improved cure rates and reduced side effects. This market taxonomy reflects innovation in multi-targeted regimens and evolving patient preferences for simplified treatment protocols.

Direct-acting Antiviral Drugs Segmentation Breakdown11 items

Application

Hospitals

Clinics

Ambulatory Surgical Centers

Pharmacies

Others

Types

NS3/4A Protease Inhibitors

Nucleoside and Nucleotide NS5B Polymerase Inhibitors

NS5A Inhibitors

Non-Nucleoside NS5B Polymerase Inhibitors

Regional Insights

Loading chart…

North America dominates the Direct-acting Antiviral Drugs market growth, accounting for the largest regional share. The region benefits from advanced healthcare infrastructure, high adoption rates of innovative therapies, and strong reimbursement policies. Government initiatives to eliminate hepatitis C, coupled with a mature ecosystem of pharmaceutical players, further drive demand. Europe follows closely, fueled by stringent regulatory frameworks ensuring drug quality and public health programs prioritizing hepatitis treatment.

Asia Pacific is the fastest-growing region, with rising HCV prevalence, expanding healthcare access, and increasing investments in diagnostics. Countries like India and China are scaling affordable treatment programs, while growing middle-class demographics boost market penetration. Latin America sees steady growth due to public-private partnerships and improved drug affordability, though infrastructure gaps temper pace. The Middle East & Africa region lags in maturity but presents untapped potential, driven by rising disease awareness and expanding healthcare ecosystems.

Key Drivers by Region5 items

North America: High R&D investments, robust telehealth adoption, and FDA fast-track approvals for novel DAAs.

Europe: Cross-border collaborations, EU-funded hepatitis eradication projects, and high patient compliance rates.

Asia Pacific: Government-led generic drug pricing policies, rising urbanization, and partnerships with global pharma firms.

Latin America: Expansion of universal health coverage and regional dengue-HCV dual-therapy research.

Middle East & Africa: Increasing geriatric populations and regional investments in infectious disease hubs.

Competitive Landscape

The Direct-acting Antiviral Drugs market is moderately consolidated, with a mix of global innovators and regional players competing on pricing, regulatory approvals, and product differentiation. While major firms like Gilead Sciences and Janssen (Johnson & Johnson) dominate through advanced treatment regimens and broad patent portfolios, emerging regional manufacturers focus on cost-competitive generics. The Direct-acting Antiviral Drugs key players leverage partnerships for pipeline development and distribution, with regulatory certifications serving as a critical barrier to entry. Pricing pressures in mature markets contrast with growth opportunities in lower-income regions, where affordability and localized manufacturing capabilities drive competition.

Competitive differentiation centers on R&D investments, therapeutic innovation, and strategic alliances. Companies pursuing M&A or R&D collaborations aim to strengthen intellectual property positions, while others prioritize cost optimization to mitigate margin erosion. A key challenge is navigating evolving regulatory requirements, which increase compliance costs and delay market access. Technology-based differentiation—such as pan-genotypic formulations or reduced treatment durations—remains a primary focus, alongside expanding into underserved patient segments through localized manufacturing and distribution networks.

Gilead Sciences: Innovation pipeline with next-generation DAAs

Janssen (Johnson & Johnson): Partnerships for global distribution networks

Merck: Cost-optimized generic formulations in emerging markets

Bristol-Myers Squibb Company: R&D focus on HCV-COVID dual-target therapies

AbbVie Inc.: Premium pricing for combination therapy regimens

Vertex Pharmaceuticals: Technology licensing for niche patient populations

Key Direct-acting Antiviral Drugs Companies12 items

AbbVie Inc.

GSK

Boehringer Ingelheim

Merck

Novartis

Beximco Pharmaceuticals

Roche

Bristol-Myers Squibb Company

Gilead Sciences

Janssen (Johnson & Johnson)

Vertex Pharmaceuticals

Natco Pharma

Market Ecosystem

The Direct-acting Antiviral Drugs ecosystem spans raw material suppliers, drug developers, manufacturers, and healthcare delivery systems. Value is generated through innovation in viral treatment protocols, efficient production processes, and clinical accessibility. Upstream participants supply active pharmaceutical ingredients and biotechnology tools, while midstream entities focus on drug formulation and regulatory compliance. Downstream actors include healthcare providers and payers who ensure patient access.

Raw material/component suppliers – Provide APIs and excipients for DAA formulation

DAA manufacturers – Develop and produce antiviral therapies with clinical validation

Technology providers – License proprietary drug delivery or viral targeting platforms

Contract manufacturing organizations (CMOs) – Scale API/finished drug production for third parties

Distributors/channel partners – Manage logistics to hospitals, pharmacies, and clinics

Healthcare providers – Prescribe DAAs and monitor treatment outcomes for patients

Regulators – Approve drug safety, efficacy, and pricing frameworks

Control points reside with regulators, who gatekeep product approval, and patent holders, who dictate technology licensing. Supply chain constraints on raw materials and high R&D costs create dependency risks. Switching costs for healthcare systems are influenced by treatment guidelines, insurance coverage, and provider training. Partnerships between manufacturers and CMOs enhance production flexibility, while regional disparities in regulatory frameworks affect market entry timelines.

Recent Industry Insights

The Direct-acting Antiviral Drugs industry trends highlight significant advancements over the past 12–18 months. Strategic partnerships have accelerated, with major players like Gilead Sciences collaborating with global health organizations to expand access to hepatitis C treatments in low-income regions. The sector also witnessed key Mergers & acquisitions, including Bristol-Myers Squibb’s acquisition of a biotech firm specializing in pan-genotypic DAA therapies, strengthening its pipeline. Product/technology launches have focused on next-generation regimens, such as Merck & Co.’s once-daily, single-tablet combination therapy, which improves patient adherence and reduces treatment duration. Regulatory bodies, including the FDA, have streamlined approvals for simplified DAA regimens, while the EMA introduced updated guidelines emphasizing risk management for drug-resistant strains. Meanwhile, consumer demand has shifted toward personalized treatment pathways, driven by advancements in genomic testing to tailor DAA therapies. Funding rounds have surged, with venture capital backing innovative startups leveraging AI to predict viral resistance patterns, signaling a tech-driven evolution in the Direct-acting Antiviral Drugs industry trends. These developments underscore a market prioritizing accessibility, precision, and rapid innovation.

Analyst Overview

The Direct-acting Antiviral Drugs market outlook remains robust, driven by rising hepatitis C prevalence, advancements in pangenotypic therapies, and expanding access in emerging economies. Market attractiveness is underscored by high patient demand for shorter treatment durations and improved cure rates, though pricing pressures from generics and biosimilars pose challenges. Competitive intensity is elevated, with Gilead Sciences, Merck & Co., and Bristol-Myers Squibb dominating, while newer entrants focus on niche segments like pediatric formulations or drug-resistant strains. Innovation is accelerating, with next-generation DAAs targeting HCV co-infections and simplified regimen designs. However, demand–supply balance faces strain in low-income regions due to cost barriers, despite robust production capacity. Key risks include regulatory scrutiny over safety profiles, patent expirations, and potential market saturation in high-income countries. Long-term growth hinges on R&D advancements, strategic partnerships, and policy reforms to ensure equitable access.

11 items

1. Executive Summary

2. Direct-acting Antiviral Drugs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Direct-acting Antiviral Drugs Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Direct-acting Antiviral Drugs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.1.3. Ambulatory Surgical Centers

6.1.4. Pharmacies

6.1.5. Others

6.2. Global Direct-acting Antiviral Drugs Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. NS3/4A Protease Inhibitors

6.2.2. Nucleoside and Nucleotide NS5B Polymerase Inhibitors

6.2.3. NS5A Inhibitors

6.2.4. Non-Nucleoside NS5B Polymerase Inhibitors

6.3. Global Direct-acting Antiviral Drugs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Direct-acting Antiviral Drugs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Direct-acting Antiviral Drugs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Direct-acting Antiviral Drugs Market Competition by Key Manufacturers

8.1. Global Direct-acting Antiviral Drugs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Direct-acting Antiviral Drugs: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. AbbVie Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. GSK

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Boehringer Ingelheim

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Merck

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Novartis

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Beximco Pharmaceuticals

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Roche

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Bristol-Myers Squibb Company

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Gilead Sciences

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Janssen (Johnson & Johnson)

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Vertex Pharmaceuticals

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Natco Pharma

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Direct-acting Antiviral Drugs Market

Figure 4: Global Direct-acting Antiviral Drugs Market: Drivers

Figure 5: Global Direct-acting Antiviral Drugs Market: Challenges

Figure 6: Global Direct-acting Antiviral Drugs Market: Trends

Figure 7: Global Direct-acting Antiviral Drugs Market: Opportunity

Figure 8: Global Direct-acting Antiviral Drugs Market: Restraint

Figure 9: Global Direct-acting Antiviral Drugs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Direct-acting Antiviral Drugs Market Value (USD Million) By Region

Figure 15: Global Direct-acting Antiviral Drugs Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Direct-acting Antiviral Drugs Market Value (USD Million) By Region

Figure 23: Global Direct-acting Antiviral Drugs Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Direct-acting Antiviral Drugs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Direct-acting Antiviral Drugs Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Direct-acting Antiviral Drugs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Direct-acting Antiviral Drugs Market Value (USD Million) By Region

Table 10: Global Direct-acting Antiviral Drugs Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Direct-acting Antiviral Drugs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Direct-acting Antiviral Drugs Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Direct-acting Antiviral Drugs Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: AbbVie Inc. Basic Information And Sales Area

Table 31: AbbVie Inc.. Products Portfolio

Table 32: GSK Basic Information And Sales Area

Table 33: GSK. Products Portfolio

Table 34: Boehringer Ingelheim Basic Information And Sales Area

Table 35: Boehringer Ingelheim. Products Portfolio

Table 36: Merck Basic Information And Sales Area

Table 37: Merck. Products Portfolio

Table 38: Novartis Basic Information And Sales Area

Table 39: Novartis. Products Portfolio

Table 40: Beximco Pharmaceuticals Basic Information And Sales Area

Table 41: Beximco Pharmaceuticals. Products Portfolio

Table 42: Roche Basic Information And Sales Area

Table 43: Roche. Products Portfolio

Table 44: Bristol-Myers Squibb Company Basic Information And Sales Area

Table 45: Bristol-Myers Squibb Company. Products Portfolio

Table 46: Gilead Sciences Basic Information And Sales Area

Table 47: Gilead Sciences. Products Portfolio

Table 48: Janssen (Johnson & Johnson) Basic Information And Sales Area

Table 49: Janssen (Johnson & Johnson). Products Portfolio

Table 50: Vertex Pharmaceuticals Basic Information And Sales Area

Table 51: Vertex Pharmaceuticals. Products Portfolio

Table 52: Natco Pharma Basic Information And Sales Area

Table 53: Natco Pharma. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Direct-acting Antiviral Drugs Market Value (USD Million) By Region

Table 59: Global Direct-acting Antiviral Drugs Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Direct-acting Antiviral Drugs Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	22.29 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AbbVie Inc.; GSK; Boehringer Ingelheim; Merck; Novartis; Beximco Pharmaceuticals; Roche; Bristol-Myers Squibb Company; Gilead Sciences; Janssen (Johnson & Johnson); Vertex Pharmaceuticals; Natco Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Direct-acting Antiviral Drugs Segmentation Breakdown11 items

Application

Hospitals

Clinics

Ambulatory Surgical Centers

Pharmacies

Others

Types

NS3/4A Protease Inhibitors

Nucleoside and Nucleotide NS5B Polymerase Inhibitors

NS5A Inhibitors

Non-Nucleoside NS5B Polymerase Inhibitors

Regional Insights

Loading chart…

Key Drivers by Region5 items

North America: High R&D investments, robust telehealth adoption, and FDA fast-track approvals for novel DAAs.

Europe: Cross-border collaborations, EU-funded hepatitis eradication projects, and high patient compliance rates.

Asia Pacific: Government-led generic drug pricing policies, rising urbanization, and partnerships with global pharma firms.

Latin America: Expansion of universal health coverage and regional dengue-HCV dual-therapy research.

Middle East & Africa: Increasing geriatric populations and regional investments in infectious disease hubs.

Competitive Landscape

Gilead Sciences: Innovation pipeline with next-generation DAAs

Janssen (Johnson & Johnson): Partnerships for global distribution networks

Merck: Cost-optimized generic formulations in emerging markets

Bristol-Myers Squibb Company: R&D focus on HCV-COVID dual-target therapies

AbbVie Inc.: Premium pricing for combination therapy regimens

Vertex Pharmaceuticals: Technology licensing for niche patient populations

Key Direct-acting Antiviral Drugs Companies12 items

AbbVie Inc.

GSK

Boehringer Ingelheim

Merck

Novartis

Beximco Pharmaceuticals

Roche

Bristol-Myers Squibb Company

Gilead Sciences

Janssen (Johnson & Johnson)

Vertex Pharmaceuticals

Natco Pharma

Market Ecosystem

Raw material/component suppliers – Provide APIs and excipients for DAA formulation

DAA manufacturers – Develop and produce antiviral therapies with clinical validation

Technology providers – License proprietary drug delivery or viral targeting platforms

Contract manufacturing organizations (CMOs) – Scale API/finished drug production for third parties

Distributors/channel partners – Manage logistics to hospitals, pharmacies, and clinics

Healthcare providers – Prescribe DAAs and monitor treatment outcomes for patients

Regulators – Approve drug safety, efficacy, and pricing frameworks

Recent Industry Insights

Analyst Overview

Table of Contents